Deutsche Bank
ARQT icon

Deutsche Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Deutsche Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Sell
382,682
-7,165
-2% -$167K ﹤0.01% 1059
2026
Q1 		$9.18M Sell
389,847
-540,355
-58% -$13.8M ﹤0.01% 1080
2025
Q4 		$27M Buy
930,202
+552,674
+146% +$14.1M 0.01% 800
2025
Q3 		$7.12M Buy
377,528
+10,113
+3% +$159K ﹤0.01% 1163
2025
Q2 		$5.15M Sell
367,415
-13,940
-4% -$195K ﹤0.01% 1225
2025
Q1 		$5.96M Sell
381,355
-6,181
-2% -$87.1K ﹤0.01% 1183
2024
Q4 		$5.4M Sell
387,536
-412,491
-52% -$4.52M ﹤0.01% 1296
2024
Q3 		$7.44M Sell
800,027
-1,081,998
-57% -$10.7M ﹤0.01% 1120
2024
Q2 		$17.5M Buy
1,882,025
+9,420
+0.5% +$85.2K 0.01% 849
2024
Q1 		$18.6M Buy
1,872,605
+478,195
+34% +$3.57M 0.01% 835
2023
Q4 		$4.5M Buy
1,394,410
+1,364,048
+4,493% +$3.71M ﹤0.01% 1295
2023
Q3 		$161K Buy
30,362
+3,655
+14% +$31.1K ﹤0.01% 2918
2023
Q2 		$255K Sell
26,707
-9,586
-26% -$106K ﹤0.01% 2750
2023
Q1 		$399K Buy
36,293
+11,121
+44% +$161K ﹤0.01% 2623
2022
Q4 		$373K Buy
25,172
+6,968
+38% +$122K ﹤0.01% 2602
2022
Q3 		$348K Buy
18,204
+555
+3% +$12.6K ﹤0.01% 2605
2022
Q2 		$376K Buy
17,649
+2,458
+16% +$50.4K ﹤0.01% 2769
2022
Q1 		$293K Sell
15,191
-1,778
-10% -$30.1K ﹤0.01% 3051
2021
Q4 		$352K Buy
16,969
+882
+5% +$17.6K ﹤0.01% 3044
2021
Q3 		$384K Sell
16,087
-1,946
-11% -$44.4K ﹤0.01% 3203
2021
Q2 		$492K Buy
18,033
+1,428
+9% +$40.2K ﹤0.01% 3228
2021
Q1 		$480K Sell
16,605
-99,330
-86% -$3.1M ﹤0.01% 3130
2020
Q4 		$3.26M Buy
115,935
+106,120
+1,081% +$2.6M ﹤0.01% 1603
2020
Q3 		$288K Buy
9,815
+5,090
+108% +$136K ﹤0.01% 2990
2020
Q2 		$143K Buy
4,725
+1,067
+29% +$30.8K ﹤0.01% 3285
2020
Q1 		$109K Buy
+3,658
New +$98.3K ﹤0.01% 3207

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Deutsche Bank's ARQT Position: Q2 2026 in Review

Deutsche Bank reduced its Arcutis Biotherapeutics (ARQT) stake by 1.8% in Q2 2026, selling an estimated $167K and leaving 382,682 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Deutsche Bank first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $27M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Deutsche Bank held 382,682 shares of Arcutis Biotherapeutics worth $10M as of Q2 2026.
  • Deutsche Bank sold 7,165 Arcutis Biotherapeutics shares in Q2 2026, an estimated $167K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1059 holding.
  • Deutsche Bank first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Deutsche Bank's Arcutis Biotherapeutics position peaked at $27M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.